Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables (2016 - 2024)

Historic Receivables for Spyre Therapeutics (SYRE) over the last 5 years, with Q4 2024 value amounting to $5.9 million.

  • Spyre Therapeutics' Receivables changed N/A to $5.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.9 million, marking a year-over-year change of. This contributed to the annual value of $5.9 million for FY2024, which is N/A changed from last year.
  • As of Q4 2024, Spyre Therapeutics' Receivables stood at $5.9 million.
  • Over the past 5 years, Spyre Therapeutics' Receivables peaked at $21.5 million during Q1 2021, and registered a low of $5.9 million during Q2 2024.